Prophylactic G-CSF in patients with early-stage breast cancer: a health economic review. - Wikidata - wikimedia - TriplyDB

Prophylactic G-CSF in patients with early-stage breast cancer: a health economic review.

Prophylactic G-CSF in patients with early-stage breast cancer: a health economic review.

http://www.wikidata.org/entity/Q37363328

about

Primary prophylactic colony-stimulating factors for the prevention of chemotherapy-induced febrile neutropenia in breast cancer patients Impact of effective prevention and management of febrile neutropenia.A prospective, controlled study of the botanical compound mixture LCS101 for chemotherapy-induced hematological complications in breast cancer Leptin-cytokine crosstalk in breast cancer.Prevention of febrile neutropenia: use of prophylactic antibiotics.Cost-effectiveness of febrile neutropenia prevention with primary versus secondary G-CSF prophylaxis for adjuvant chemotherapy in breast cancer: a systematic review.Primary prophylaxis with granulocyte colony-stimulating factor (GCSF) reduces the incidence of febrile neutropenia in patients with non-Hodgkin lymphoma (NHL) receiving CHOP chemotherapy treatment without adversely affecting their quality of life: c Costs associated with febrile neutropenia in the US.

P2860

Q24198118-B441C9B4-32D2-4785-A2EC-2090330177FB Q33503548-886B2624-22C2-44B7-81F4-0956DB732E80 Q35584817-E6DA1929-8E8A-4212-A35F-CA1A9506116B Q37351155-930A3822-E70F-4A67-8FF9-5870F3EC4603 Q37363337-8043A418-F1F2-476B-969C-72D9578C3BFD Q38940016-4942F7FB-F132-474E-B848-8B4DFB0AAA32 Q40274712-69C5D7A6-E777-4405-9DCF-73685295707F Q40280346-353FA91E-DB38-45E7-A392-646CCA67CFFB

P2860

Prophylactic G-CSF in patients with early-stage breast cancer: a health economic review.

http://www.wikidata.org/entity/Q37363328

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on September 2009

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Prophylactic G-CSF in patients with early-stage breast cancer: a health economic review.

@en

Prophylactic G-CSF in patients with early-stage breast cancer: a health economic review.

@nl

type

label

Prophylactic G-CSF in patients with early-stage breast cancer: a health economic review.

@en

Prophylactic G-CSF in patients with early-stage breast cancer: a health economic review.

@nl

prefLabel

Prophylactic G-CSF in patients with early-stage breast cancer: a health economic review.

@en

Prophylactic G-CSF in patients with early-stage breast cancer: a health economic review.

@nl

P1433

Q37363328-1877DCE8-58C8-45A9-A6B2-9351A2ABB3CF

P1476

Q37363328-DF003330-9467-4ADA-9600-CF0731921E70

P2093

Q37363328-D9E61C8A-6B41-4621-BE93-94F81AC65813

P2860

Q37363328-082B8CB6-39C4-4441-9118-29C75F0F578A

Q37363328-41F3F784-CFA8-4809-98A8-CAAB8562F2AF

Q37363328-5489A6B8-E840-432C-A533-B44ADE456965

Q37363328-694313B6-44D8-4BA9-A52D-C3C7008F2A3E

Q37363328-87816AC4-B27C-4DB6-9FF3-62AD29C8EBC2

Q37363328-C40C44BA-8FAF-4796-ADDF-B2C591621B08

Q37363328-C993ACEC-55D4-4A84-8C9E-4A26F7FCFB2F

Q37363328-ED48C8C1-DA2C-449B-BE3D-F4573BC298BB

Q37363328-FC898DD3-7A9E-4C81-A32B-5392ABA3EA8A

P2888

Q37363328-7C97567C-5A6D-4633-9E20-86B85254F46A

P304

Q37363328-977B7641-3F00-40F1-8B8A-F4AAF106D3E1

P31

Q37363328-68552AD9-A9D9-4DC9-8F3F-36126A2E168D

P356

Q37363328-55DEB0E4-7C51-4F79-B86E-BC83F5940EB8

P407

Q37363328-42DE4891-598A-42C8-8439-F9A9CBAAEA3A

P478

Q37363328-B3B204C1-B888-4FD3-9A58-36E682F69951

P577

Q37363328-74D24136-ABB8-4B6F-8E66-9080239B835D

P5875

Q37363328-83D0A8F8-4494-4E23-8699-B83ECAD35F22

P6179

Q37363328-74F29E24-599C-491A-9112-4A9BDF287E8B

P698

Q37363328-278EEF46-DA02-421D-8817-EC686344690D

P932

Q37363328-C4113D1B-E6F0-47E8-BA73-BC48F4C3C936

P356

P1433

British Journal of Cancer

P1476

Prophylactic G-CSF in patients with early-stage breast cancer: a health economic review.

@en

P2093

P Trueman

http://www.w3.org/2001/XMLSchema#string

P2860

2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline.

Mortality, morbidity, and cost associated with febrile neutropenia in adult cancer patients.

EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphomas and solid tumours.

Prevention of febrile neutropenia: use of granulocyte colony-stimulating factors.

Prevention of febrile neutropenia: use of prophylactic antibiotics.

Myeloid growth factors.

When the risk of febrile neutropenia is 20%, prophylactic colony-stimulating factor use is clinically effective, but is it cost-effective?

Evaluating the total costs of chemotherapy-induced febrile neutropenia: results from a pilot study with community oncology cancer patients.

Economic analysis of prophylactic pegfilgrastim in adult cancer patients receiving chemotherapy.

P2888

P304

S15-7

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/SJ.BJC.6605271

http://www.w3.org/2001/XMLSchema#string

P407

P478

101 Suppl 1

http://www.w3.org/2001/XMLSchema#string

P577

2009-09-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

26813815

http://www.w3.org/2001/XMLSchema#string

P6179

1000313709

http://www.w3.org/2001/XMLSchema#string

P698

19756001

http://www.w3.org/2001/XMLSchema#string

P932

2752222

http://www.w3.org/2001/XMLSchema#string